ImmunityBio

In 2024, the FDA approved over 130 drugs, including 40 novel ones. Madrigal's Rezdiffra is the first treatment for MASH, X4's Xolremdi for WHIM syndrome, Day One's Ojemda for pediatric low-grade glioma, Geron's Rytelo for MDS, and ImmunityBio's Anktiva for NMIBC. These approvals mark significant milestones for these companies and address high unmet medical needs.

The lung cancer therapeutics market is projected to grow from USD 37.5 billion in 2024 to USD 112.8 billion by 2034, driven by increased prevalence, advanced therapeutics, and innovative treatment options. Cell and gene therapies are emerging as transformative, with precision medicine and immuno-oncology combination therapies driving growth. Key regions like North America, Europe, and Asia-Pacific are expected to dominate, with significant growth in countries like India, China, and South Korea.

ImmunityBio partners with nCartes to automate clinical trial data collection, aiming to reduce costs, improve quality, and expedite trial outcomes by directly populating EDC systems from EMR data.

ImmunityBio and nCartes collaborate to automate clinical trial data fulfillment, aiming to streamline processes, reduce costs, and minimize errors by leveraging EMR systems to populate EDC systems directly.

N-803 plus BCG showed 71% complete response in BCG-unresponsive NMIBC CIS patients in QUILT 3.023 trial, with response durations up to 54 months. ImmunityBio plans to submit an MAA to EMA in Q4 2024. FDA approved N-803 in April 2024.